Cargando…

Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study

The 21-gene recurrence score (RS) is increasingly being used for patients with early stage, hormone receptor-positive, Her-2-negative breast cancer. However, these results are largely from populations with infiltrating ductal carcinoma (IDC). The clinical value of RS testing in mucinous carcinoma ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Wei, Chen, Xiaosong, Lin, Lin, Fei, Xiaochun, Garfield, David H., Hong, Jin, Gao, Weiqi, Zhu, Siji, Wu, Jiayi, Huang, Ou, He, Jianrong, Li, Yafen, Zhu, Li, Chen, Weiguo, Shen, Kunwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160674/ https://www.ncbi.nlm.nih.gov/pubmed/30271480 http://dx.doi.org/10.7150/jca.27291

Ejemplares similares

Comprehensive Association Analysis of 21-Gene Recurrence Score and Obesity in Chinese Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2021)

Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study
por: Wu, Jiayi, et al.
Publicado: (2020)

Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
por: Yu, Jing, et al.
Publicado: (2021)

Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients
por: Wu, Jiayi, et al.
Publicado: (2017)

A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab
por: Hong, Jin, et al.
Publicado: (2019)

Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
por: Chen, Xiaosong, et al.
Publicado: (2015)

Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample
por: Zhu, Siji, et al.
Publicado: (2019)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients
por: Lu, Yujie, et al.
Publicado: (2020)

Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?
por: Yu, Jing, et al.
Publicado: (2020)

Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26–30
por: Yu, Jing, et al.
Publicado: (2020)

A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer
por: Lin, Caijin, et al.
Publicado: (2020)

Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment
por: Zhu, Siji, et al.
Publicado: (2021)

A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis
por: Hong, Jin, et al.
Publicado: (2020)

Presence of CHD1L Over-Expression Is Associated with Aggressive Tumor Biology and Is a Novel Prognostic Biomarker for Patient Survival in Human Breast Cancer
por: Wu, Jiayi, et al.
Publicado: (2014)

Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study
por: Zong, Yu, et al.
Publicado: (2014)

Changes of Tumor Infiltrating Lymphocytes after Core Needle Biopsy and the Prognostic Implications in Early Stage Breast Cancer: A Retrospective Study
por: Huang, Jiahui, et al.
Publicado: (2019)

The Comparative Safety of Epirubicin and Cyclophosphamide versus Docetaxel and Cyclophosphamide in Lymph Node-Negative, HR-Positive, HER2-Negative Breast Cancer (ELEGANT): A Randomized Trial
por: Liu, Deyue, et al.
Publicado: (2022)

HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab
por: Li, Shuai, et al.
Publicado: (2020)

Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
por: Li, Shuai, et al.
Publicado: (2021)

Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis
por: Hong, Jin, et al.
Publicado: (2020)

IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2020)

A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age
por: Yu, Jing, et al.
Publicado: (2021)

Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score
por: Gao, Weiqi, et al.
Publicado: (2020)

Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer
por: Chen, Xiaosong, et al.
Publicado: (2013)

Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer
por: Li, Shuai, et al.
Publicado: (2022)

Biomarkers of Insulin and the Insulin-Like Growth Factor Axis in Relation to Breast Cancer Risk in Chinese Women
por: Zhu, Yifei, et al.
Publicado: (2020)

Associations Between Circulating Insulin-Like Growth Factor 1 and Mortality in Women With Invasive Breast Cancer
por: Zhu, Yifei, et al.
Publicado: (2020)

Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion
por: Fang, Yan, et al.
Publicado: (2016)

Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis
por: Wu, Chenghui, et al.
Publicado: (2023)

Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients
por: Fang, Yan, et al.
Publicado: (2020)

Impact of clinicopathological factors on extended endocrine therapy decision making in estrogen receptor–positive breast cancer
por: Chen, Weilin, et al.
Publicado: (2023)

Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era
por: Liang, Yue, et al.
Publicado: (2019)

Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy
por: Huang, Renhong, et al.
Publicado: (2023)

Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer
por: Gao, Weiqi, et al.
Publicado: (2019)

Prognostic and predictive value of Ki-67 in triple-negative breast cancer
por: Wang, Wei, et al.
Publicado: (2016)

A senescence-associated signature refines the classification of different modification patterns and characterization of tumor immune microenvironment infiltration in triple-negative breast cancer
por: Huang, Renhong, et al.
Publicado: (2023)

Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer
por: Huang, Renhong, et al.
Publicado: (2023)

Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases
por: Zhu, Siji, et al.
Publicado: (2023)

Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component
por: Zeng, Yufei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n21ph6fr8qeua4dbf4260js2bk